2-(苄氧基)-6-羟基苯甲酸甲酯 | 74292-74-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(苄氧基)-6-羟基苯甲酸甲酯
• 英文名称: methyl 2-(benzyloxy)-6-hydroxybenzoate
• 英文别名: methyl 2-hydroxy-6-(benzyloxy)benzoate；methyl 2-benzyloxy-6-hydroxybenzoate；2-benzyloxy-6-hydroxy-benzoic acid methyl ester；methyl-2-benzyloxy-6-hydroxybenzoate；methyl 2-hydroxy-6-phenylmethoxybenzoate
• CAS: 74292-74-3
• 化学式: C₁₅H₁₄O₄
• 分子量: 258.274
• InChiKey: KWPSQXPDPNPBMS-UHFFFAOYSA-N

物化性质

• 沸点：
  396.9±27.0 °C(Predicted)
• 密度：
  1.227±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  2-(苄氧基)-6-羟基苯甲酸甲酯 在 sodium hydroxide 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 24.0h， 以92%的产率得到2-(benzyloxy)-6-hydroxybenzoic acid
  参考文献：
  名称：

  Design of HIV-1 integrase inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75: A scaffold hopping approach using salicylate and catechol groups

  摘要：

  HIV-1 integrase (IN) is a validated therapeutic target for antiviral drug design. However, the emergence of viral strains resistant to clinically studied IN inhibitors demands the discovery of novel inhibitors that are structurally as well mechanistically different. Herein, we describe the design and discovery of novel IN inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75, which is essential for the HIV-1 integration as an IN cofactor. By merging the pharmacophores of salicylate and catechol, the 2,3-dihydroxybenzamide (5a) was identified as a new scaffold to inhibit the strand transfer reaction efficiently. Further structural modifications on the 2,3-dihydroxybenzamide scaffold revealed that the heteroaromatic functionality attached on the carboxamide portion and the piperidin-1-ylsulfonyl substituted at the phenyl ring are beneficial for the activity, resulting in a low micromolar IN inhibitor (5p, IC(50) = 5 mu M) with more than 40-fold selectivity for the strand transfer over the 3'-processing reaction. More significantly, this active scaffold remarkably inhibited the interaction between IN and LEDGF/p75 cofactor. The prototype example, N-(cyclohexylmethyl)-2,3-dihydroxy-5-(piperidin-1-ylsulfonyl) benzamide (5u) inhibited the IN-LEDGF/p75 interaction with an IC(50) value of 8 mu M. Using molecular modeling, the mechanism of action was hypothesized to involve the chelation of the divalent metal ions inside the IN active site. Furthermore, the inhibitor of IN-LEDGF/p75 interaction was properly bound to the LEDGF/p75 binding site on IN. This work provides a new and efficient approach to evolve novel HIV-1 IN inhibitors from rational integration and optimization of previously reported inhibitors. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.06.058
• 作为产物：
  描述：

  2,6-二羟基苯甲酸 在 四丁基碘化铵 、 sodium hydride 作用下， 反应 2.17h， 生成 2-(苄氧基)-6-羟基苯甲酸甲酯
  参考文献：
  名称：

  2-（烷基氨基）烟酸及其类似物。强大的血管紧张素II拮抗剂。

  摘要：

  人们发现，通过-CH2-NR'-连接（1）连接到联苯四唑的一系列吡啶和其他六元环杂环是有效的血管紧张素II拮抗剂。在嘧啶羧酸系列中（W = CR，X = N，Y = CH，Z = COOH），环外氮上带有烷基（R'）的化合物比带有烷基（R）的化合物更有效在杂环上。相应的吡啶，哒嗪，吡嗪和1,2,4-三嗪羧酸也显示出有效的体外血管紧张素II拮抗作用。吡啶（W，X，Y = CH，Z = COOH，R'= n-C3H7）具有很强的体外活性（pA2 = 10.10，兔主动脉，Ki = 0.61 nM，大鼠肝脏中的受体结合）以及出色的口服降压活性和生物利用度。

  DOI：

  10.1021/jm00070a012

文献信息

• [DE] DIBENZOXAZEPINE<br/>[EN] DIBENZOXAZEPINE<br/>[FR] DIBENZOXAZEPINES
  申请人：BAYER HEALTHCARE AG

  公开号：WO2004033437A1

  公开（公告）日：2004-04-22

  Die vorliegende Erfindung betrifft Verbindungen, Verfahren zur ihrer Herstellung, sie umfassende pharmazeutische Zusammensetzungen sowie ihre Verwendung bei der Behandlung und/oder Prophylaxe von Erkrankungen bei Menschen oder Tieren, insbesondere von Herz-Kreislauf-Erkrankungen, z. B. von Atherosklerose.

  本发明涉及化合物、其制备方法、包括它们的药物组合物以及它们在治疗和/或预防人类或动物疾病，特别是心血管疾病，例如动脉粥样硬化方面的用途。
• IL-8 receptor antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US06204294B1

  公开（公告）日：2001-03-20

  This invention relates to novel compounds of Formula (1), pharmaceutical compositions and their use in the treatment of disease states mediated by the chemokine, Interleukins-8 (IL-8).

  这项发明涉及到Formula (1)的新化合物，药物组合物以及它们在治疗由趋化因子Interleukins-8 (IL-8)介导的疾病状态中的应用。
• Synthesis and Absolute Configuration of (−)-3-Butyl-7-hydroxyphthalide, a Cytotoxic Metabolite of<i>Penicillium vulpinum</i>*
  作者：Tomoya OHZEKI、Kenji MORI

  DOI：10.1271/bbb.67.2240

  日期：2003.1

  Both the enantiomers as well as the racemate of 3-butyl-7-hydroxyphthalide (1) were synthesized, and the absolute configuration of the naturally occurring (−)-1 (a weakly cytotoxic metabolite of Penicillium vulpinum) was identified as S.

  合成了 3-丁基-7-羟基苯酞（1）的对映体和外消旋体，并确定了天然存在的 (-)-1（Penicillium vulpinum 的一种弱细胞毒性代谢物）的绝对构型为 S。
• Selective mono O-alkylation of γ-resorcylic esters
  作者：R.J. Bass、B.J. Banks、M. Snarey

  DOI：10.1016/s0040-4039(00)71469-9

  日期：1980.1

  The use of diethylazodicarboxylate/triphenylphosphine for the selective mono-O-alkylation of γ-resorcylic esters is described.

  描述了偶氮二羧酸二乙酯/三苯基膦用于γ-间苯二酸酯的选择性单-O-烷基化的用途。
• Benzisoxazole Derivatives
  申请人：Noguchi Hirohide

  公开号：US20080207690A1

  公开（公告）日：2008-08-28

  This invention relates to compounds of the formula (I): wherein A, B, R 1 , R 4 , m, and n are each as described herein or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT 4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central 10 nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.

  本发明涉及化合物的公式（I）：其中A，B，R1，R4，m和n分别如本文所述或其药学上可接受的盐，并包含这些化合物的组合物以及这些化合物在治疗由5-HT4受体活性介导的疾病中的使用，例如但不限于胃食管反流病，胃肠道疾病，胃动力障碍，非溃疡性消化不良，功能性消化不良，肠易激综合症（IBS），便秘，消化不良，食管炎，胃食管疾病，恶心，中枢神经系统疾病，阿尔茨海默病，认知障碍，呕吐，偏头痛，神经系统疾病，疼痛，心血管疾病，如心力衰竭和心律失常，糖尿病和呼吸暂停综合症。